Search for Clinical Trial Results

Sponsored By

Primary Myelofibrosis - 25 Studies Found

Status Study
Active, not recruiting Study Name: Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis
Condition: Myelofibrosis
Date: 2012-12-24
Interventions: Drug: Peginterferon alfa-2a 50 mcg subcutaneous injection once per week
Suspended Study Name: Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor
Condition: Primary Myelofibrosis
Date: 2015-04-21
Interventions:
  • Drug: Imetelstat 9.4 milligram/kilogram (mg/kg)

Terminated Study Name: A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)
Condition: Primary Myelofibrosis
Date: 2014-03-06
Interventions: Drug: Ruxolitinib Starting dose was based on reason for previous discontinuation of ruxolitinib (i.e. lo
Completed Study Name: Thalidomide in Treating Patients With Myelofibrosis
Condition: Primary Myelofibrosis
Date: 2001-05-06
Interventions:
  • Drug: thalidomide Given PO
Withdrawn Study Name: A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis
Condition: Primary Myelofibrosis
Date: 2015-10-21
Interventions: Biological: Pacritinib QD (Once a day)
Completed Study Name: Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis
Condition: Myelofibrosis
Date: 2010-06-22
Interventions: Drug: APLIDIN (plitidepsin) Aplidin® (plitidepsin) ly
Active, not recruiting Study Name: Decitabine in Treating Patients With Myelofibrosis
Condition:
  • Primary Myelofibrosis
  • Secondary Myelofibr
    Date: 2004-11-09
    Interventions:
    • Drug: Decitabine Given SC
Recruiting Study Name: P1101 in Treating Patients With Myelofibrosis
Condition:
  • Primary Myelofibrosis
  • Secondary Myelofibr
    Date: 2015-02-17
    Interventions:
    • Other: Laboratory Biomarker Analysis

Recruiting Study Name: Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg
Condition: Myelofibrosis
Date: 2016-03-08
Interventions:
  • Drug: Ruxolotinib Ruxolitinib

Active, not recruiting Study Name: Phase-3 Double-Blind, Placebo-Controlled Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Myelofibrosis and RBC-Transfusion-Dependence
Condition: Primary Myelofibrosis
Date: 2010-07-15
Interventions:
  • Drug: Pomalidomide 0.5 mg Poma
Next >>>